DCGI approves emergency use of Bharat Biotech’s Covaxin for children aged 6-12 years

ANI news agency, on Tuesday, reported that the Drugs Controller General of India (DCGI) has approved the emergency use authorisation for Bharat Biotech’s Covaxin for children aged 6-12 years.

The DGCI has asked vaccine manufacturers to submit safety data including the data on adverse events with due analysis every 15 days for the first two months and monthly thereafter for up to 5 months, said the source familiar with the development.

This development comes after the Subject Expert Committee (SEC) discussed recommendations for the restricted emergency use of Covaxin in children aged between 2-12 years. However, the SEC, after a meeting on Thursday, had recommended restricted emergency use of Biological E’s Covid-19 vaccine, Corbevax, in children aged 5-12 years.